Global Schizophrenia Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027
-
2088
-
May 2023
-
159
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Global Schizophrenia Market Overview
"The Schizophrenia Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031."
Schizophrenia is a chronic mental disorder that affects how a person thinks, feels, and acts. Individuals with schizophrenia may find it difficult to distinguish between what is real and imaginary and may be unresponsive at times.
Also, individuals affected by schizophrenia may have difficulty expressing normal emotions in various social situations. The exact cause of schizophrenia is unknown, but some theories about the cause include; genetics (heredity), biology (abnormalities in the brain’s chemistry or structure), and/or possible viral infections and immune disorders. The treatments for schizophrenia include antipsychotics and specialty care.
Increasing incidence of schizophrenia in developed economies, growing awareness among individuals about treatments for schizophrenia, and increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving the growth of the global schizophrenia drugs market. In addition, relatively high number of pipeline drugs, and availability of cost effective generic schizophrenia drugs are other factors expected to boost growth of the global schizophrenia drugs market over the forecast period.
However, high cost of therapies for treating schizophrenia and side effects caused by the intake of generic schizophrenia drugs are major factors restraining growth of the global schizophrenia drugs market. Additionally, lack of appropriate healthcare infrastructure in emerging economies and high cots in R&D of schizophrenia drugs are other factors expected to hamper growth of the global schizophrenia drugs market over the forecast period.
Currently, North America dominates the global schizophrenia market in revenue terms owing to the presence of a large patient pool and the availability of appropriate healthcare infrastructure in the region. The market in Europe accounted for the second-highest revenue share in the global schizophrenia market due to high healthcare expenditure by governments of countries, and increasing awareness about mental disorders, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to have the fastest growth in revenue, owing to the presence of a large patient pool and the availability of generic drugs for schizophrenia treatment in the region.
Global Schizophrenia Market Segmentation:
Global schizophrenia market segmentation by therapeutic class:
- Second-Generation Antipsychotics
- Risperdal (Risperidone)
- Invega (Paliperidone)
- Zyprexa (Olanzapine)
- Geodon (Ziprasidone)
- Seroquel (Quetiapine)
- Latuda (Lurasidone)
- Aristada (Aripiprazole Lauroxil)
- Fanapt (Iloperidone)
- Saphris (Asenapine)
- Vraylar (Cariprazine)
- Third-Generation Antipsychotics
- Abilify (Aripiprazole)
- Others
- First-Generation Antipsychotics
- Generics
Global schizophrenia market segmentation by treatment:
- Oral Antipsychotics
- Injectable Antipsychotics
Global schizophrenia market segmentation by region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn - Second-Generation Antipsychotics
-
-
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company/Otsuka Holdings Co. Ltd.
- AstraZeneca
- Dainippon Sumitomo Pharma Co., Ltd.
- Alkermes
- Eli Lilly and Company
- Vanda Pharmaceuticals Inc.
- Allergan plc
- Pfizer Inc.
Our Clients
View Our Licence Options
